Moderna, Inc. Common Stock
MRNA XNAS
$172.94
+18.85 (+12.24%)
▲
15-min delayed
Open
$161.05
High
$176.86
Low
$159.06
Volume
21.04M
Market Cap
$61.50B
About Moderna, Inc. Common Stock
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $145.00M | $-782,000,000 | $-1.97 |
| Q1 2026 | $389.00M | $-1,343,000,000 | $-3.40 |
| FY 2025 | $1.94B | $-2,822,000,000 | $-7.26 |
| Q3 2025 | $1.02B | $-200,000,000 | $-0.51 |
TickerDaily Coverage
Healthcare Stocks This Week: XLV Gains 2.1% as UNH, LLY Lead Sector Rally (Aug 3–7, 2026)
Market News
David Brooks · Aug 7, 2026
The healthcare sector finished the week with solid momentum, as the Health Care Select Sector SPDR...
Pre-Market Movers: Top Stocks Making Biggest Moves Before the Bell Today (July 6)
Market News
Sarah Mitchell · Jul 6, 2026
Five major stocks are making significant pre-market moves ahead of Monday's opening bell on July 6,...
Healthcare Stocks This Week: XLV Outperforms on Rate Cut Bets — Weekly Roundup (Jun 29 – Jul 3, 2026)
Market News
David Brooks · Jul 3, 2026
The healthcare sector capped a record-breaking first half with a strong week as XLV rallied on...
View All Coverage →
Get MRNA Alerts
Stay ahead with breaking news, price alerts, and expert analysis on Moderna, Inc. Common Stock.
Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.